Arcellx/$ACLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcellx
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Ticker
$ACLX
Sector
Primary listing
Employees
163
Headquarters
Website
Arcellx Metrics
BasicAdvanced
$4.7B
-
-$3.43
0.28
-
Price and volume
Market cap
$4.7B
Beta
0.28
52-week high
$107.37
52-week low
$47.86
Average daily volume
515K
Financial strength
Current ratio
3.807
Quick ratio
3.746
Long term debt to equity
11.498
Total debt to equity
13.389
Interest coverage (TTM)
-205.75%
Profitability
EBITDA (TTM)
-208.075
Gross margin (TTM)
-202.30%
Net profit margin (TTM)
-329.93%
Operating margin (TTM)
-376.26%
Effective tax rate (TTM)
-0.94%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-19.80%
Return on equity (TTM)
-42.75%
Valuation
Price to revenue (TTM)
81.919
Price to book
12.01
Price to tangible book (TTM)
12.01
Price to free cash flow (TTM)
-37.873
Free cash flow yield (TTM)
-2.64%
Free cash flow per share (TTM)
-2.246
Growth
Revenue change (TTM)
-60.64%
Earnings per share change (TTM)
223.66%
3-year earnings per share growth (CAGR)
-19.10%
Bulls say / Bears say
Phase 2 iMMagine-1 data showed an overall response rate of 97% and a complete response/stringent complete response rate of 68% in 117 RRMM patients at a median follow-up of 12.6 months, with median progression-free survival and overall survival not yet reached (Reuters).
The safety profile remains positive, with no delayed neurotoxicities—including no Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)—and no immune-mediated enterocolitis reported in the pivotal study (Reuters).
Arcellx closed Q2 2025 with $538 million in cash, extending its operational runway into 2028 to support late-stage development and preparations for the anticipated commercial launch in 2026 (Reuters).
Net loss increased to $52.8 million in Q2 2025 from $27.2 million in the previous year, reflecting higher general and administrative costs related to commercial preparation (Reuters).
Collaboration revenue dropped to $7.6 million in Q2 2025 from $27.4 million in Q2 2024, falling short of analyst expectations and underscoring the unpredictable nature of milestone-related income before product launch (Reuters).
Although the safety profile remains clear so far, the appearance of neurotoxicity or other safety concerns could significantly hinder market uptake of anito-cel, particularly as CAR-T therapies face intense scrutiny (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcellx stock?
Arcellx (ACLX) has a market cap of $4.7B as of October 04, 2025.
What is the P/E ratio for Arcellx stock?
The price to earnings (P/E) ratio for Arcellx (ACLX) stock is 0 as of October 04, 2025.
Does Arcellx stock pay dividends?
No, Arcellx (ACLX) stock does not pay dividends to its shareholders as of October 04, 2025.
When is the next Arcellx dividend payment date?
Arcellx (ACLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcellx?
Arcellx (ACLX) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.